NCT02089269Completed
Tumor Registry Pancreatic Cancer
Clinical Registry on Treatment Reality and Sequential Treatments of Patients with Resectable or Locally Advanced/metastatic Pancreatic Cancer in Real-life Practice in Germany
Source: ClinicalTrials.gov · Last updated 30 Jan 2025
Brief summary (registry, in English)
The registry aims to collect and analyse information on the antineoplastic treatment of patients with unresectable locally advanced or metastatic pancreatic cancer, treated in palliative intention (cohort 1) and patients with localized, resectable pancreatic cancer treated in neo-adjuvant or adjuvant intention (cohort 2) in daily routine practice in Germany. The registry will follow up patients for two years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. Health-related quality of life will be analysed during the course of the treatment (PanLife). Based on the available data a prognostic score will be developed.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2325 (actual)
- First submitted
- 14 Mar 2014
- Start date
- Dec 2013
- Primary completion date
- 14 Apr 2022
- Lead sponsor
- iOMEDICO AG
- Diseases
- Pancreatic cancer
- NCT number
- NCT02089269
What you commit to
- Study type: Observational
- Participants enrolled: 2325
- From Dec 2013 to the primary completion date, 14 Apr 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- No pancreatic cancer
Other
- Below 18 years and older
- No antineoplastic treatment
- Date of consent later than 2 weeks after start of first-line treatment
Who the study is looking for
- resectable or locally advanced/metastatic pancreatic cancer
- 18 years and older
- Antineoplastic treatment
- Date of consent no later than 2 weeks after start of first-line treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| iOMEDICO Coordinator of this site? Confirm its status | Freiburg im Breisgau | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.